MX2020009900A - Formulaciones peptidicas especificas para el receptor de melanocortinas y metodos para un suministro especifico en el tubo gastrointestinal. - Google Patents

Formulaciones peptidicas especificas para el receptor de melanocortinas y metodos para un suministro especifico en el tubo gastrointestinal.

Info

Publication number
MX2020009900A
MX2020009900A MX2020009900A MX2020009900A MX2020009900A MX 2020009900 A MX2020009900 A MX 2020009900A MX 2020009900 A MX2020009900 A MX 2020009900A MX 2020009900 A MX2020009900 A MX 2020009900A MX 2020009900 A MX2020009900 A MX 2020009900A
Authority
MX
Mexico
Prior art keywords
specific
gastrointestinal tract
methods
melanocortin receptor
peptide formulations
Prior art date
Application number
MX2020009900A
Other languages
English (en)
Spanish (es)
Inventor
Stephen Kwaku Dordunoo
John Harold Dodd
Original Assignee
Palatin Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palatin Technologies Inc filed Critical Palatin Technologies Inc
Publication of MX2020009900A publication Critical patent/MX2020009900A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
MX2020009900A 2018-03-23 2019-03-22 Formulaciones peptidicas especificas para el receptor de melanocortinas y metodos para un suministro especifico en el tubo gastrointestinal. MX2020009900A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862647000P 2018-03-23 2018-03-23
PCT/US2019/023575 WO2019183472A1 (en) 2018-03-23 2019-03-22 Melanocortin receptor-specific peptide formulations and methods for gastrointestinal tract-specific delivery

Publications (1)

Publication Number Publication Date
MX2020009900A true MX2020009900A (es) 2021-01-08

Family

ID=67988087

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020009900A MX2020009900A (es) 2018-03-23 2019-03-22 Formulaciones peptidicas especificas para el receptor de melanocortinas y metodos para un suministro especifico en el tubo gastrointestinal.

Country Status (13)

Country Link
US (1) US20220088146A1 (enExample)
EP (1) EP3768245A4 (enExample)
JP (1) JP2021523931A (enExample)
KR (1) KR102743821B1 (enExample)
CN (1) CN112188888A (enExample)
AU (2) AU2019239300A1 (enExample)
BR (1) BR112020019128A2 (enExample)
CA (1) CA3095036A1 (enExample)
EA (1) EA202092275A1 (enExample)
IL (1) IL277496B2 (enExample)
MX (1) MX2020009900A (enExample)
PH (1) PH12020551596A1 (enExample)
WO (1) WO2019183472A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021158463A1 (en) 2020-02-03 2021-08-12 Palatin Technologies, Inc. Diamine-linked receptor-specific cyclic peptides
TW202440065A (zh) * 2022-12-28 2024-10-16 日商中外製藥股份有限公司 包含分散對象物質的固體分散體、包含其之醫藥組合物及其製造方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7645459B2 (en) * 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of bisphosphonates
FR2937868B1 (fr) * 2008-11-04 2010-11-05 Galderma Res & Dev Composes antagonistes des recepteurs de la melanocortine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
BRPI1009644B1 (pt) * 2009-06-08 2022-02-08 Palatin Technologies, Inc Peptídeo cíclico ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica e uso da composição farmacêutica
WO2010144341A2 (en) * 2009-06-08 2010-12-16 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
AU2010321738B2 (en) * 2009-11-23 2016-07-14 Palatin Technologies, Inc. Melanocortin-1 receptor-specific cyclic peptides
US8759386B2 (en) * 2011-01-24 2014-06-24 Boehringer Ingelheim International Gmbh Pyrazole compounds as CRTH2 antagonists
KR102038677B1 (ko) * 2011-06-14 2019-10-30 입센 파마 에스.에이.에스 활성 성분으로 멜라노코르틴 수용체 리간드를 함유하는 지속-방출형 조성물
SI2659881T1 (en) * 2012-04-30 2018-03-30 Tillotts Pharma Ag Formulation of the delayed release medicinal product
UA119335C2 (uk) * 2013-12-11 2019-06-10 Айронвуд Фармасьютикалз, Інк. Композиції лінаклотиду з затриманим вивільненням
US20150307754A1 (en) * 2014-04-28 2015-10-29 Celanese Acetate Llc Adhesives that include highly-plasticized cellulose esters and methods and articles relating thereto
US10588864B2 (en) * 2016-03-11 2020-03-17 Gateway Pharmaceuticals LLC Pharmaceutical compositions for colon-specific delivery

Also Published As

Publication number Publication date
EP3768245A1 (en) 2021-01-27
US20220088146A1 (en) 2022-03-24
IL277496A (en) 2020-11-30
IL277496B2 (en) 2025-01-01
IL277496B1 (en) 2024-09-01
AU2025201154A1 (en) 2025-03-13
CN112188888A (zh) 2021-01-05
JP2021523931A (ja) 2021-09-09
KR20210003759A (ko) 2021-01-12
EP3768245A4 (en) 2023-10-18
KR102743821B1 (ko) 2024-12-18
CA3095036A1 (en) 2019-09-26
PH12020551596A1 (en) 2021-08-16
WO2019183472A1 (en) 2019-09-26
AU2019239300A1 (en) 2020-11-19
BR112020019128A2 (pt) 2021-01-12
EA202092275A1 (ru) 2021-02-09

Similar Documents

Publication Publication Date Title
PH12020551742A1 (en) Gip derivatives and uses thereof
MX2025003235A (es) Composiciones y metodos para el suministro de proteinas de membrana
PH12020500500A1 (en) Pyrazolopyrimidinone compounds and uses thereof
MX2021005092A (es) Andamiajes de la subunidad a de la toxina shiga desinmunizados y moleculas con direccion a las celulas que los comprenden.
MX356295B (es) Análogos de péptido de la hormona de estimulación de alfa-melanocito.
MX394873B (es) Sistemas y metodo para suministro de gas terapeutico a pacientes en necesidad del mismo usando la medicion de flujo de gas de circuito de respiracion (bcg) mejorada
PH12020551018A1 (en) Oral delivery of glp-1 peptide analogs
MY187047A (en) Selective pyy compounds and uses thereof
GEP20217326B (en) Constructs having a sirp-alpha domain or variant thereof
MX2012007806A (es) Composiciones farmaceuticas para administracion oral de peptidos de insulina.
MX2015015249A (es) Peptidos terapeuticos.
MX2026000051A (es) Peptidos penetrantes celulares
ZA202103867B (en) Tubulysins and protein-tubulysin conjugates
PH12019550241A1 (en) Mic-1 compounds and uses thereof
WO2017093810A3 (en) Composition for intraoral delivery of biologically active peptides and proteins
PH12020551596A1 (en) Melanocortin receptor-specific peptide formulations and methods for gastrointestinal tract-specific delivery
CL2015002620A1 (es) Derivados piridin-4-ilo
MX2009013682A (es) Enlazador de fmoc polimerico hidrolizable.
MX2017006437A (es) Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor.
WO2010144341A3 (en) Lactam-bridged melanocortin receptor-specific peptides
MX2021013341A (es) Formas solidas de un inhibidor de glyt1.
EA201700019A1 (ru) Высокочистый оритаванцин и способ его получения
EP3530671A3 (en) Gip peptide analogues
MX2020013389A (es) Composiciones de terlipresina y usos de las mismas.
MX2022009398A (es) Péptidos cíclicos específicos de receptores unidos a diamina.